Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Gross Margin (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Gross Margin for 6 consecutive years, with 52.92% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 563.0% year-over-year to 52.92%, compared with a TTM value of 51.84% through Dec 2025, down 358.0%, and an annual FY2025 reading of 51.84%, down 358.0% over the prior year.
  • Gross Margin was 52.92% for Q4 2025 at Cytek Biosciences, roughly flat from 52.69% in the prior quarter.
  • Across five years, Gross Margin topped out at 66.36% in Q3 2022 and bottomed at 48.62% in Q1 2025.
  • Average Gross Margin over 5 years is 57.36%, with a median of 56.74% recorded in 2023.
  • The sharpest move saw Gross Margin plummeted -4664bps in 2021, then surged 447bps in 2022.
  • Year by year, Gross Margin stood at 60.77% in 2021, then grew by 0bps to 60.77% in 2022, then fell by -7bps to 56.75% in 2023, then rose by 3bps to 58.55% in 2024, then decreased by -10bps to 52.92% in 2025.
  • Business Quant data shows Gross Margin for CTKB at 52.92% in Q4 2025, 52.69% in Q3 2025, and 52.34% in Q2 2025.